Vertex Pharmaceuticals Inc (VRTX) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Total Assets Chart for Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc (VRTX) total assets for FY2025 were USD 26.1B, a 16.0% change from FY2024. Vertex Pharmaceuticals Inc's total assets grew from USD 9.2M in 1990 to USD 26.1B in 2025 (284060.9% over 35 years). Total assets compound annual growth rate: 5-year CAGR of 17.3%, 10-year CAGR of 26.5%, 20-year CAGR of 21.3%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $141.65B
- Implied Share Price
- $558.88
- Enterprise Value
- $135.78B
- Revenue (TTM)
- $12.59B
- EBITDA
- $5.10B
- Profit Margin
- 35.00%
- Trailing P/E
- 32.55
- Forward P/E
- 26.39
- Price/Book (MRQ)
- 7.00
- Price/Sales (TTM)
- 11.25
- EV/EBITDA
- 26.62
- EV/Revenue
- 10.79
- Dividend Yield
- —
- Book Value
- $79.92
- Free Cash Flow (FY2025)
- $3.19B
- Free Cash Flow Yield
- 2.25%
Snapshot as of 1st November 2026 — not point-in-time controlled, may lag the live market by a few days.